[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE299023T1 - Integrinrezeptor antagonisten - Google Patents

Integrinrezeptor antagonisten

Info

Publication number
ATE299023T1
ATE299023T1 AT98963893T AT98963893T ATE299023T1 AT E299023 T1 ATE299023 T1 AT E299023T1 AT 98963893 T AT98963893 T AT 98963893T AT 98963893 T AT98963893 T AT 98963893T AT E299023 T1 ATE299023 T1 AT E299023T1
Authority
AT
Austria
Prior art keywords
beta
alpha
receptor antagonists
integrin receptor
compounds
Prior art date
Application number
AT98963893T
Other languages
English (en)
Inventor
Mark E Duggan
James J Perkins
Robert S Meissner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807384.4A external-priority patent/GB9807384D0/en
Priority claimed from GBGB9815803.3A external-priority patent/GB9815803D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE299023T1 publication Critical patent/ATE299023T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98963893T 1997-12-17 1998-12-14 Integrinrezeptor antagonisten ATE299023T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6990997P 1997-12-17 1997-12-17
GBGB9807384.4A GB9807384D0 (en) 1998-04-06 1998-04-06 Vitronectin receptor antagonists
US8325098P 1998-04-27 1998-04-27
US9263098P 1998-07-13 1998-07-13
GBGB9815803.3A GB9815803D0 (en) 1998-07-21 1998-07-21 Vitronectin receptor antagonists
PCT/US1998/026485 WO1999030713A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE299023T1 true ATE299023T1 (de) 2005-07-15

Family

ID=27517454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963893T ATE299023T1 (de) 1997-12-17 1998-12-14 Integrinrezeptor antagonisten

Country Status (8)

Country Link
EP (1) EP1044001B1 (de)
JP (1) JP2002508326A (de)
AT (1) ATE299023T1 (de)
AU (1) AU738452B2 (de)
CA (1) CA2315232A1 (de)
DE (1) DE69830806T2 (de)
ES (1) ES2243015T3 (de)
WO (1) WO1999030713A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100506A4 (de) * 1998-07-29 2002-06-26 Merck & Co Inc Integrin rezeptor antagonisten
JP2002522540A (ja) * 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
JP2002536411A (ja) 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー Ｘａ因子のラクタム系阻害剤および方法
TR200102944T2 (tr) 1999-04-13 2002-08-21 Basf Aktiengesellschaft İntegrin reseptör ligandları
WO2000072801A2 (en) 1999-06-02 2000-12-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
EP1229910A4 (de) 1999-10-04 2003-10-01 Merck & Co Inc Integrinrezeptorantagonisten
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2001269876A1 (en) 2000-06-15 2001-12-24 Mark Laurence Boys Heteroarylalkanoic acids as integrin receptor antagonists
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
JP2004509123A (ja) 2000-09-14 2004-03-25 メルク　エンド　カムパニー　インコーポレーテッド アルファνインテグリン受容体アンタゴニスト
MXPA03006772A (es) 2001-01-29 2004-10-15 Dimensional Pharm Inc Indoles sustituidos y su uso como antogonistas de integrina.
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
PT1539739E (pt) * 2002-08-16 2011-01-05 Janssen Pharmaceutica Nv Compostos de piperidinilo que ligam selectivamente integrinas
JP2006516144A (ja) 2002-12-20 2006-06-22 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
LT3050878T (lt) 2013-09-24 2021-12-10 Fujifilm Corporation Naujas azotą turintis junginys arba jo druska, arba jo metalo kompleksas
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
MX2021002181A (es) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibicion de la integrina alfa v beta 6.
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CA3116769C (en) 2018-10-30 2023-08-22 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929618A (en) * 1988-03-25 1990-05-29 Ube Industries, Ltd. Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
EP1044001A1 (de) 2000-10-18
WO1999030713A1 (en) 1999-06-24
DE69830806T2 (de) 2006-04-27
CA2315232A1 (en) 1999-06-24
AU738452B2 (en) 2001-09-20
DE69830806D1 (de) 2005-08-11
JP2002508326A (ja) 2002-03-19
EP1044001A4 (de) 2003-01-29
AU1912899A (en) 1999-07-05
EP1044001B1 (de) 2005-07-06
ES2243015T3 (es) 2005-11-16

Similar Documents

Publication Publication Date Title
ATE294163T1 (de) Integrin-rezeptor-antagonisten
ATE298338T1 (de) Integrin-rezeptor-antagonisten
ATE299023T1 (de) Integrinrezeptor antagonisten
ATE236626T1 (de) Integrin antagonist
CA2277273A1 (en) Integrin antagonists
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
DE60035779D1 (de) Alpha v integrin-rezeptor antagonisten
YU38200A (sh) Antagonisti integrinskog receptora
YU38300A (sh) Antagonisti integrinskog receptora
ECSP992897A (es) Antagonistas del receptor de integrina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties